Attorney General Gentner Drummond of Oklahoma recently filed a lawsuit against major diabetic drug manufacturers and PBMs, alleging an unfair and deceptive pricing scheme that has cost patients billions. Drummond claims violations of the Oklahoma Consumer Protection Act and said that manufacturers have significantly increased the prices of diabetes drugs despite reduced production costs. Just as damning, the lawsuit accuses these companies of coordinating to control drug prices and purchasing behavior. Filed in Cleveland County District Court, the suit targets several prominent companies, including Eli Lilly, Novo Nordisk, and CVS Health Corp. Insulin, which originally sold for $20 in the late 1990s, now ranges from $300 to $700, with prices hiked up to 1,000 percent in the last decade. The lawsuit also emphasizes the impact on Oklahoma's population, which has high rates of diabetes, forcing many to ration medication due to affordability issues, leading to serious health complications and increased health care costs.
NCPA
